Study to Evaluate the Safety and Efficacy of | Clinical Research Studies Listing

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Stage 2 and 3 Neurotrophic Keratitis Subjects

Recruiting

18 years - 99 years

All

Phase 1

5 participants needed

1 Location

Brief description of study

The purpose of this study is to compare the safety and effectiveness of the study product, CSB-001 ophthalmic solution 0.1% to placebo when treating stage 2 and 3 Neurotrophic Keratitis.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Neurotrophic Keratitis
Age: 18 years - 99 years
Gender: All

Male or Female, Age 18 or older Subjects with stage 2 (PED) or stage 3 (corneal ulcer) NK

Updated on 04 Aug 2024. Study ID: 849886

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Stage 2 and 3 Neurotrophic Keratitis Subjects

Brief description of study

Eligibility of study

Find a site

Interested in the study